Abstract
Despite the lack of placebo-controlled trials, glucocorticoids are considered the mainstay of initial treatment for idiopathic inflammatory myopathy (IIMs) and myositis-associated ILD (MA-ILD). Glucocorticoid-sparing agents are often given concomitantly with other immunosuppressive agents, particularly in patients with moderate or severe disease. As treatment of refractory cases of idiopathic inflammatory myopathies has been challenging, there is growing interest in evaluating newer therapies including biologics that target various pathways involved in the pathogenesis of IIMs. In a large clinical trial of rituximab in adult and juvenile myositis, the primary outcome was not met, but the definition of improvement was met by most of this refractory group of myositis patients. Rituximab use was also associated with a significant glucocorticoid-sparing effect. Intravenous immune globulin (IVIg) can be used for refractory IIMs or those with severe dysphagia or concomitant infections. Anti-tumor necrosis factor (anti-TNF) utility in IIMs is generally limited by previous negative studies along with recent reports suggesting their potential for inducing myositis. Further research is required to assess the role of new therapies such as tocilizumab (anti-IL6), ACTH gel, sifalimumab (anti-IFNα), and abatacept (inhibition of T cell co-stimulation) given their biological plausibility and encouraging small case series results. Other potential novel therapies include alemtuzumab (a humanized monoclonal antibody which binds CD52 on B and T lymphocytes), fingolimod (a sphingosine 1-phosphate receptor modulator that traps T lymphocytes in the lymphoid organs), eculizumab, and basiliximab. The future investigations in IIMs will depend on well-designed controlled clinical trials using validated consensus core set measures and improvements in myositis classification schemes based on serologic and histopathologic features.
Similar content being viewed by others
References
Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65(2):314–324
Bunch TW, Worthington JW et al (1980) Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med 92(3):365–369
Dalakas MC, Illa I, Dambrosia JM et al (1993) A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329(27):1993–2000
Miller FW, Leitman SF, Cronin ME et al (1992) Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 326(21):1380–1384
Troyanov Y, Targoff IN, Tremblay JL et al (2005) Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 84(4):231–249
Koenig M, Fritzler MJ, Targoff IN et al (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9(4):R78
Rider LG, Werth VP, Huber AM et al (2011) Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: physician and patient/parent global activity, manual muscle testing (MMT), health assessment questionnaire (HAQ)/childhood health assessment questionnaire (C-HAQ), childhood myositis assessment scale (CMAS), myositis disease activity assessment tool (MDAAT), disease activity score (DAS), short form 36 (SF-36), child health questionnaire (CHQ), physician global damage, myositis damage index (MDI), quantitative muscle testing (QMT), myositis functional index-2 (FI-2), myositis activities profile (MAP), inclusion body myositis functional rating scale (IBMFRS), cutaneous dermatomyositis disease area and severity index (CDASI), cutaneous assessment tool (CAT), dermatomyositis skin severity index (DSSI), skindex, and dermatology life quality index (DLQI). Arthritis Care Res 63(Suppl 11):S118–S157
Oddis CV, Rider LG, Reed AM et al (2005) International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 52(9):2607–2615
Isenberg DA, Allen E, Farewell V et al (2004) International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 43(1):49–54
R Aggarwal, LG Rider, N Ruperto, N Bayat, B Erman, BM Feldman, A Huber, CV Oddis, I Lundberg, AA Amato, RG Cooper, H Chinoy, M Dastmalchi, D Fiorentino, D Isenberg, JD Katz, A Mammen, M de Visser, SR Ytterberg, D. Katalin, L Villa, M Rinaldi, H Rockette, P Lachenbruch, F Miller, J Vencovsky. A (2014) Consensus Hybrid Definition using a Conjoint Analysis is Proposed as Response Criteria for Minimal and Moderate Improvement in Adult Polymyositis and Dermatomyositis Clinical Trials. Arthritis Rheum 64(10 Suppl).
Mahler EA, Blom M, Voermans NC et al (2011) Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 50(12):2206–2213
Valiyil R, Casciola-Rosen L, Hong G et al (2010) Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 62(9):1328–1334
Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52(2):601–607
Mok CC, Ho LY, To CH (2007) Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol 34(9):1864–1868
Chung L, Genovese MC, Fiorentino DF (2007) A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol 143(6):763–767
Brulhart L, Waldburger JM, Gabay C (2006) Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 65(7):974–975
Lambotte O, Kotb R, Maigne G, Blanc FX, Goujard C, Delfraissy JF (2005) Efficacy of rituximab in refractory polymyositis. J Rheumatol 32(7):1369–1370
Arlet JB, Dimitri D, Pagnoux C et al (2006) Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 16(5):334–336
Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, Rider LG, Harris-Love MO, Levesque MC (2014) RIM Study Group, Oddis CV. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 66(3):740–749
Kalluri M, Oddis CV (2010) Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med 31:501–512
Marie I, Hachulla E, Chérin P et al (2002) Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 47:614–622
Keir GJ, Maher TM, Ming D et al (2014) Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19:353–359
Andersson H, Sem M, Lund MB, Aaløkken TM, Günther A, Walle-Hansen R, Garen T, Molberg Ø (2015) Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford) 54:1420–1428
Cherin P, Pelletier S, Teixeira A et al (2002) Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 46(2):467–474
Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10(3):144–149
Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y (2012) GB-0998 Study Group. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol 22(3):382–393
Suzuki Y, Hayakawa H, Miwa S et al (2009) Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 187:201–206
Bakewell CJ, Raghu G (2011) Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 139:441–443
Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT (2012) Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 78(13):1009–1015
Iannone F, Scioscia C, Falappone PC et al (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33(9):1802–1804
Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70(3):427–436
Hengstman GJ, van den Hoogen FH, Barrera P et al (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50(1):10–15
Selva-O’Callaghan A, Martínez-Costa X, Solans-Laque R et al (2004) Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology (Oxford) 43(9):1196–1197
Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 44(4):562–563
Hengstman GJ, van den Hoogen FH, van Engelen BG (2004) Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol 52(1):61–63
Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65(9):1233–1236
Dastmalchi M, Grundtman C, Alexanderson H et al (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67(12):1670–1677
Coyle K, Pokrovnichka A, French K (2008) A randomized double blind placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis. Arthritis Res 58:S293
Hengstman GJ, De Bleecker JL, Feist E (2008) Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 59(3–4):159–163
Riolo G, Towheed TE (2012) Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J Rheumatol 39(1):192–194
Klein R, Rosenbach M, Kim EJ et al (2010) Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 146(7):780–784
Ishikawa Y, Yukawa N, Ohmura K et al (2010) Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 29(5):563–566
Brunasso AM, Scocco GL, Massone C (2010) Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 37(7):1549–1550
Lepidi H, Frances V, Figarella-Branger D et al (1998) Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 24(1):73–79
Gabay C, Gay-Croisier F, Roux-Lombard P et al (1994) Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 37(12):1744–1751
Lundberg I, Ulfgren AK, Nyberg P et al (1997) Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum 40(5):865–874
Narazaki M, Hagihara K, Shima Y (2011) Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 50(7):1344–1346
Kondo M, Murakawa Y, Matsumura T, Matsumoto O, Taira M, Moriyama M, Sumita Y, Yamaguchi S (2014) A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford) 53(10):1907–1908
Thompson B, Corris P, Miller JA et al (2008) Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol 35(10):2080–2082
Murata K, Dalakas MC (1999) Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155(2):453–460
Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, Tresser N, Abati A, Fetsch P, Plotz PH (1999) Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 92(2):161–169
Musuruana JL, Cavallasca JA (2011) Abatacept for treatment of refractory polymyositis. Joint Bone Spine 78(4):431–432
Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160(3):520–522
Maeshima K, Kiyonaga Y, Imada C, Iwakura M, Hamasaki H, Haranaka M, Ishii K (2014) Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology (Oxford) 53(2):379–380
Kerola AM, Kauppi MJ (2015) Abatacept as a successful therapy for myositis—a case-based review. Clin Rheumatol 34(3):609–612
Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA (2005) Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57(5):664–678
Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA (2007) Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 56(11):3784–3792
Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13(1–2):59–68
Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM (2009) Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60(11):3436–3446
Higgs BW, Zhu W, Morehouse C et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73(1):256–262
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moghadam-Kia, S., Oddis, C.V. & Aggarwal, R. Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clinic Rev Allerg Immunol 52, 81–87 (2017). https://doi.org/10.1007/s12016-016-8530-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-016-8530-2